BioNTech reports unbelievable YoY growth for its fiscal Q4

BioNTech SE shares (NASDAQ: BNTX) opened 8% up on Wednesday after the pharmaceutical company handily beat Street expectations for Q4 earnings and revenue.

Notable figures in BioNTech Q4 earnings report

Comirnaty sales outlook for 2022

According to the earnings press release, in 2021, BioNTech delivered 2.6 billion doses of Comirnaty – its COVID shot that it developed in collaboration with Pfizer.

New vaccine orders now stand at 2.4 billion doses for 2022. The German firm expects up to €17 billion in revenue from Comirnaty this year. This, however, compares to an even higher €17.59 billion that analysts anticipate.

Nonetheless, the boost from COVID vaccine sales will see BioNTech spend roughly €1.50 billion on R&D in 2022; about a 50% increase from what was indicated previously. Other than COVID-19, R&D will also focus on oncology and infectious diseases.

A day earlier, CDC recommended fourth dose of Comirnaty for people aged fifty and above.